Metraipolis › archive › dc_bda83446b2d3

Tumor Regression Grade as a Predictor of Adjuvant Therapy Benefits in Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Therapy — Europe PMC PMID:40944434

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40944434
DOI
10.1002/cam4.71166
License (as archived)
solo-consultazione
Archived
2026-11-10T05:54:03.780Z
SHA-256 of the archived text
f7d34ff3ba4d360c0e3761113033c74718ce490d1e81094f89ccfc5aab2ef85e
Stable URL of this page
https://metraipolis.com/documento/dc_bda83446b2d3

How to cite

Tumor Regression Grade as a Predictor of Adjuvant Therapy Benefits in Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Therapy — Europe PMC PMID:40944434 — Europe PMC (en), https://europepmc.org/article/MED/40944434 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bda83446b2d3 (Metraipolis archive dc_bda83446b2d3, sha256 f7d34ff3ba4d360c0e3761113033c74718ce490d1e81094f89ccfc5aab2ef85e)
BibTeX
@misc{dcbda83446b2d3,
  title = {Tumor Regression Grade as a Predictor of Adjuvant Therapy Benefits in Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Therapy — Europe PMC PMID:40944434},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40944434},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bda83446b2d3; sha256 f7d34ff3ba4d360c0e3761113033c74718ce490d1e81094f89ccfc5aab2ef85e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40944434. Agents can read the archived copy with the MCP tool read_document.